5 6 7 8

found Documents: 374

Announcements & Press Releases, Oncology / Immunology, Press Releases | 28 Nov 2019

Chi-Med’s Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China

1 item

London: Thursday, November 28, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Elunate® (fruquintinib capsules), its national class 1 targeted anticancer drug for the treatment of patients with advanced

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 25 Nov 2019

Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors

1 item

London: Monday, November 25, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug designation to surufatinib for the treatment of pancr

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 23 Nov 2019

Chi-Med Highlights Oral Presentations at 2019 ESMO Asia Annual Meeting

1 item

London: Saturday, November 23, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shared analyses from two clinical studies of savolitinib and fruquintinib at the fifth European Society for Medical Oncology Asia Congress (“ESM

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology | 11 Nov 2019

Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors

1 item

London: Monday, November 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its New Drug Application (“NDA”) for surufatinib for the treatment of patients with advanced non-pancreatic neuroendocrine

View Announcement (PDF)

Group, Press Releases | 11 Nov 2019

Chi-Med to Attend Upcoming Investor and Industry Conferences

1 item

London: Monday, November 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the following conferences: Deutsche Bank Depositary Receipts Virt

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 Oct 2019

Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers

1 item

London: Thursday, October 17, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today highlighted the publication of results from the Phase II VIKTORY (targeted agent eValuation In gastric cancer basKeT KORea studY) trial in Ca

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Oct 2019

Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

1 item

Suzhou, China and London, UK, Thursday, October 10, 2019 — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) and Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the expansion of their global collaboration ag

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 4 Oct 2019

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma

1 item

London: Friday, October 4, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with relapsed or refr

Download Press Release (PDF)

Announcements & Press Releases, Group | 30 Sep 2019

CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Monday, September 30, 2019: Hutchison Chin

View Announcement (PDF)

Announcements & Press Releases, Group | 30 Sep 2019

CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Sep 2019

Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting

1 item

Press Release – Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients with non-pancreatic neuroendocrine tumors (“NET”) in the Phase III SANET-ep study – – Preparations underway for the potent

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 25 Sep 2019

Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting

1 item

– Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors (“NET”) to be presented – – Conference call and webcast with lead trial investigators to be held on Mond

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 18 Sep 2019

Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting

1 item

London: Wednesday, September 18, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of fruquintinib and savolitinib at the 22nd Annual Meeting of the C

Download Press Release (PDF)

Announcements & Press Releases, Group, Press Releases | 3 Sep 2019

Chi-Med to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

1 item

London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley 17th Annual Global Healthcare C

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 3 Sep 2019

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma

1 item

London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 23 Aug 2019

Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China

1 item

London: Friday, August 23, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with immune thrombocytopenia (“ITP”

Download Press Release (PDF)

Announcements & Press Releases, Group | 30 Jul 2019

Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs

1 item

London: Tuesday, July 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs. Major highlight

Download Announcement (PDF)

Announcements & Press Releases, Group | 3 Jul 2019

Chi-Med to Announce 2019 Half-Year Financial Results

1 item

London: Wednesday, July 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm

View Announcement (PDF)

Announcements & Press Releases, Group | 28 Jun 2019

Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering of American Depositary Shares

1 item

Download Announcement (PDF)

Announcements & Press Releases, Group | 27 Jun 2019

Chi-Med Announces Secondary Offering of American Depositary Shares

1 item

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 Jun 2019

Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early

1 item

London: Friday, June 14, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the Phase III pivotal study of surufatinib in advanced neuroendocrine tum

Download Press Release (PDF)

Announcements & Press Releases, Group | 29 May 2019

Results of Extraordinary General Meeting

1 item

London: Wednesday, May 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the ordinary resolution and special resolution put to its Extraordinary General Meeting (“EGM”) held on May 29, 2019 were dul

Download Announcement (PDF)

Announcements & Press Releases, Group | 3 May 2019

Notice of Extraordinary General Meeting and Shareholders' Circular

1 item

London: Friday, May 3, 2019: Hutchison China MediTech Limited (“Chi-Med” or “Company”) (AIM/Nasdaq: HCM) today announces that an Extraordinary General Meeting (“EGM”) is to be held at 11:00 a.m. London time on Wednesday, May 29, 2019. An

Download Announcement (PDF)

Announcements & Press Releases, Group | 15 Apr 2019

Chi-Med Files Application to List in Hong Kong and Announces Proposed Global Offering

1 item

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Mar 2019

Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China

1 item

London: Friday, March 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a registration-enabling Phase IIb/III study comparing surufatinib (HMPL-012 or sulfatinib) with capecitabine in patients with advanced

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 28 Mar 2019

Chi-Med Highlights Oral Presentations on Savolitinib Lung Cancer Programs at AACR Annual Meeting

1 item

Press Release London: Thursday, March 28, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will share further data on the savolitinib development programs in lung cancer at the American Association of Cancer Research (AACR)

Download Press Release (PDF)

Announcements & Press Releases, Group | 21 Mar 2019

2018 Annual Report and Notice of Annual General Meeting

1 item

London: Thursday, March 21, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2018 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders

Download Announcement (PDF)

Announcements & Press Releases, Group | 11 Mar 2019

Publication of Form 20-F

1 item

London: Monday, March 11, 2019: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2018. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/r

View Form 20-F (PDF)

Announcements & Press Releases, Group | 11 Mar 2019

Chi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs

1 item

London: Monday, March 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its audited financial results for the year ended December 31, 2018 and provides updates on key clinical programs. Video webcas

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 12 Feb 2019

Chi-Med Highlights Preliminary Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2019 ASCO Genitourinary Cancers Symposium

1 item

London: Tuesday, February 12, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of preliminary results from the Phase II CALYPSO study of the savolitinib / Imfinzi® (durvalumab) combination in

Download Press Release (PDF)

Announcements & Press Releases, Group | 8 Feb 2019

Chi-Med to Announce 2018 Final Results

1 item

London: Friday, February 8, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2018 on Monday, March 11, 2019 at 7:00 am Greenwich Mean Time (GMT). An analyst pr

Download Announcement (PDF)

Announcements & Press Releases, Group, Press Releases | 7 Jan 2019

Chi-Med to Present at the 37th Annual JP Morgan Healthcare Conference

1 item

Press Release London: Monday, January 7, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37th Annual JP Morgan Healthcare Conference on Wednes

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 20 Dec 2018

Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company

1 item

– Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China – – Chi-Med to assume all development costs of life cycle indications in

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 20 Dec 2018

Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy

1 item

– Global SAVANNAH study of savolitinib / Tagrisso®combination in MET+ EGFRm NSCLC underway. Data presented at ESMO 2018 showedMET-amplification among the most frequent mechanisms of acquired resistance to AstraZeneca’s Tagrisso® – – China

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Nov 2018

Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors

1 item

London: Thursday, November 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib (HMPL-012 or sulfatinib) a

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 26 Nov 2018

Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)

1 item

London: Monday, November 26, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the first commercial launch of fruquintinib capsules (Elunate®) with the initiation of product sales in China. Elunate® is for the

Download Press Release (PDF)

Oncology / Immunology | 20 Nov 2018

Chi-Med Receives BayHelix R&D Achievement of the Year Award at BioCentury China Healthcare Summit

1 item

Shanghai: November 20, 2018: Hutchison China MediTech (“Chi-Med”) received “R&D Achievement of the Year” Award from BayHelix at the BioCentury China Healthcare Summit on November 14, 2018. Hutchison MediPharma, the Innovation Platform

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology | 16 Nov 2018

Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China

1 item

– Trial did not meet the primary endpoint of overall survival despite improvement in progression-free survival – London: Friday, November 16, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the outcome of

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 18 Oct 2018

Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China

1 item

London: Thursday, October 18, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in combination with azacitidine, an approved nuc

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology | 5 Sep 2018

Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China

1 item

– Fruquintinib capsules provide a new oral treatment option for patients with metastatic colorectal cancer and will be marketed as Elunate® – – Elunate® data published in JAMA demonstrated increased overall survival versus placebo – – F

View Announcement (PDF)

Announcements & Press Releases, Group | 27 Jul 2018

Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs

1 item

London: Friday, July 27, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2018 and updates shareholders on key clinical programs. Fruquinti

View Full Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 23 Jul 2018

Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Sulfatinib in Pancreatic Neuroendocrine Tumors and Biliary Tract Cancer in the United States

1 item

London: Monday, July 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase Ib/II proof-of-concept study of sulfatinib in pancreatic neuroendocrine tumors (“NET”) patients and in biliary tract cancer (�

Download Press Release (PDF)

Announcements & Press Releases, Group, Press Releases | 29 Jun 2018

Chi-Med to Announce 2018 Half-Year Financial Results

1 item

London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday, July 27, 2018 at 7:00 am British Summer Time (BST). An analy

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 4 Jun 2018

Chi-Med Presents Further Fruquintinib FRESCO Trial Data at ASCO 2018 Annual Meeting

1 item

Press Release – Chi-Med makes additional FRESCO presentations at ASCO 2018, following oral presentation at ASCO 2017 showing that study met all endpoints with a manageable safety profile and lower off-target toxicities compared to other targeted t

Download Press Release (PDF)

Announcements & Press Releases, Group, Press Releases | 11 May 2018

Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference

Press Release London: Friday, May 11, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that Christian Hogg, Chief Executive Officer, will present at the Bank of America Merrill Lynch 2018 Health Care Confe

Announcements & Press Releases, Group | 26 Mar 2018

2017 Annual Report and Notice of Annual General Meeting

1 item

London: Monday, March 26, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2017 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders.�

View Announcement (PDF)

Announcements & Press Releases, Group | 12 Mar 2018

Publication of Form 20-F for the Year Ended December 31, 2017

1 item

View Form 20-F (PDF)

Announcements & Press Releases, Group | 12 Mar 2018

Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs

1 item

Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs Group: Year of major progress; results in line with guidance Group revenue up 12% to $

View Full Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 6 Mar 2018

Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China

1 item

London: Tuesday, March 6, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase Ib/II proof-of-concept study of epitinib in glioblastoma patients with epidermal growth factor receptor (“EGFR”) gene amplifi

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 13 Feb 2018

Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer

1 item

London: Tuesday, February 13, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has completed patient enrollment of FALUCA, its Phase III pivotal trial of fruquintinib in advanced, third-line, non-small cell lung cancer (“NSC

Download Press Release (PDF)

1 2 3

5 6 7 8